Stories – Eye on Innovation

This unique Mayo Clinic resource offers a novel portal into the study of gene mutations before they cause breast cancer.

By Chris Bahnsen • June 8, 2022

As Mayo Clinic’s Anatomic Pathology moves from traditional glass slides to digital images, the advance in technology is achieving clear benefits in collaboration, learning, and patient care.

By Chris Bahnsen • May 11, 2022

In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides answers.

By Barbara J. Toman • April 13, 2022

Successful implementation of a new slide scanning and analysis platform across five laboratories represents a significant step forward in Mayo Clinic’s digital pathology program — an initiative that combines advanced technology with human expertise to better serve patients.

By Chris Bahnsen • March 9, 2022

Experts at Mayo Clinic have developed a unique method of testing that combines new technology with novel bioinformatics to promptly detect a group of uncommon genetic conditions that are often difficult to identify.

By Tracy Will • February 9, 2022

To safeguard patient samples, staff in Mayo Clinic’s Histology Laboratory devised an inventive way to ensure that none of the paraffin-embedded blocks processed in the lab ever ends up in the trash.

By Tracy Will • January 12, 2022

The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.

By Robin Huiras-Carlson • December 8, 2021

As chair of Mayo Clinic’s new Division of Computational Pathology and AI in the Department of Laboratory Medicine and Pathology, Jason Hipp, M.D., Ph.D., is eager to employ the most innovative tools available to benefit patients around the globe.

By Tracy Will • November 10, 2021

In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity and 100% specificity. This is the first assay of its kind that can detect viral antigens “directly from clinical specimens” such as nasopharyngeal swabs. Mass spectrometry is a sensitive technique used to detect, identify, and quantitate molecules present in a sample.   

By Chris Bahnsen • October 13, 2021

A web of innovation within Mayo Clinic Laboratories links research and test development with clinical practice, enabling for some of the world’s most pioneering methodologies. Underpinning this innovation network are unique supports that provide inventive and essential solutions to broaden testing capabilities.

By Robin Huiras-Carlson • September 8, 2021

It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear may allow for improved recognition of this uncommon cause of Lyme disease.

By Tracy Will • August 11, 2021

Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.

By Robin Huiras-Carlson • July 14, 2021

The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.

By Robin Huiras-Carlson • June 9, 2021